William Rigby, MD
Enriched profileInterim Section Chief of Rheumatology; Professor of Medicine and Professor of Microbiology and Immunology, Geisel School of Medicine at Dartmouth · Dartmouth-Hitchcock Medical Center
William Rigby is Interim Section Chief of Rheumatology; Professor of Medicine and Professor of Microbiology and Immunology, Geisel School of Medicine at Dartmouth at Dartmouth-Hitchcock Medical Center. OpenAlex indexes 125 publications with 6,655 citations (h-index 44); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
William F.C. Rigby, MD, is Interim Section Chief of Rheumatology at Dartmouth-Hitchcock Medical Center / Geisel School of Medicine at Dartmouth. The public record shows 125 publications with 6,655 citations (h-index 44), centered on Rheumatoid Arthritis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 6 companies, 9 NIH-funded awards (1985–2013).
- Most recent indexed publication: 2026 · medRxiv
- Top research focus: Rheumatoid Arthritis
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Rheumatoid Arthritis Memory B Cells and Abatacept
Sponsor: NYU Langone Health
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- ABBVIE INC.Program year20251 payment
- GENZYME CORPORATIONProgram year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.7%Corticosteroid33%Prednisone100%Part D≥46 patientsProton pump inhibitor4.7%Omeprazole100%Part D<11 patientsCancer & immunology
29.3%Folate Analog Metabolic Inhibitor15.8%Methotrexate100%Part D≥25 patientsTNF inhibitor7.4%Humira Pen53%Enbrel47%Part D<11 patientsMusculoskeletal
10.2%Xanthine oxidase inhibitor10.2%Allopurinol100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
9 NIH research awards on record, funded 1985–2013 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Differential Enhancement of Neutrophil Phagocytosis by Anti-Bactericidal/Permeability-Increasing Protein Antibodies.
Journal of immunology (Baltimore, Md.
Article2021 - Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia.
Infection and immunity
Article2020 - Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.
International journal of rheumatology
Review2017
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/william-rigby-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
rheumnow.com/user/27830
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumnow.com ↗ - ResearchGate
researchgate.net/profile/William-Rigby
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →neurosciencecme.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →geiselmed.dartmouth.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →geiselmed.dartmouth.edu ↗
- Board certified
Internal Medicine and Rheumatology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →geiselmed.dartmouth.edu ↗
- Interim Section Chief of Rheumatology
Dartmouth-Hitchcock Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗ - Principal Investigator
Rigby Laboratory, Geisel School of Medicine at Dartmouth
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →geiselmed.dartmouth.edu ↗
Awards & honors
honors on the public record- Recognized by the American College of Rheumatology (ACR) in an official ACR post honoring William Rigby
MD, of Dartmouth-Hitchcock Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
Secondary affiliations
appointments beyond the home institution- Immunology Program
Dartmouth
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →geiselmed.dartmouth.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →geiselmed.dartmouth.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →geiselmed.dartmouth.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University